SC
VKTX icon

Scotia Capital’s Viking Therapeutics VKTX Stock Holding History

Scotia Capital’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$235K Sell
6,031
-1,017
-14% -$32.9K ﹤0.01% 821
2026
Q1 		$229K Sell
7,048
-416
-6% -$13.4K ﹤0.01% 830
2025
Q4 		$263K Sell
7,464
-60,425
-89% -$2.14M ﹤0.01% 778
2025
Q3 		$1.78M Buy
67,889
+25,755
+61% +$768K 0.01% 466
2025
Q2 		$1.12M Buy
+42,134
New +$1.11M 0.01% 510

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Scotia Capital's VKTX Position: Q2 2026 in Review

Scotia Capital reduced its Viking Therapeutics (VKTX) stake by 14% in Q2 2026, selling an estimated $32.9K and leaving 6,031 shares worth $235K. The position accounts for ﹤0.01% of the portfolio, ranked #821.

Scotia Capital first reported a position in VKTX in Q2 2025 and has held it in 5 quarters since. The position peaked at $1.78M in Q3 2025. 432 funds tracked by Wall St. Rank hold VKTX as of Q2 2026.

  • Scotia Capital held 6,031 shares of Viking Therapeutics worth $235K as of Q2 2026.
  • Scotia Capital sold 1,017 Viking Therapeutics shares in Q2 2026, an estimated $32.9K.
  • Viking Therapeutics made up ﹤0.01% of Scotia Capital's portfolio in Q2 2026, its #821 holding.
  • Scotia Capital first reported a position in Viking Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • Scotia Capital's Viking Therapeutics position peaked at $1.78M in Q3 2025.
  • 432 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2026.

Based on Scotia Capital's 13F filing for Q2 2026, filed 11 Aug 2026.